

Vasilis Stavrinides,, Mrcs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7186874/publications.pdf>

Version: 2024-02-01

37
papers

529
citations

687220

13
h-index

677027

22
g-index

37
all docs

37
docs citations

37
times ranked

799
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>European Urology</i> , 2020, 78, 443-451.	0.9	94
2	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. <i>European Urology</i> , 2020, 78, 163-170.	0.9	60
3	Outcome in surgically treated Rathke's cleft cysts: long-term monitoring needed. <i>European Journal of Endocrinology</i> , 2011, 165, 33-37.	1.9	38
4	Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. <i>European Radiology</i> , 2021, 31, 1644-1655.	2.3	37
5	MRI in active surveillance: a critical review. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 5-15.	2.0	36
6	The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing. <i>Cancers</i> , 2019, 11, 1233.	1.7	31
7	Stroma in normal and cancer wound healing. <i>FEBS Journal</i> , 2019, 286, 2909-2920.	2.2	27
8	Orchidopexy for Testicular Torsion: A Systematic Review of Surgical Technique. <i>European Urology Focus</i> , 2021, 7, 1493-1503.	1.6	22
9	Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. <i>European Radiology</i> , 2020, 30, 2082-2090.	2.3	20
10	Cellular senescence as a possible link between prostate diseases of the ageing male. <i>Nature Reviews Urology</i> , 2021, 18, 597-610.	1.9	19
11	Image quality assessment for machine learning tasks using meta-reinforcement learning. <i>Medical Image Analysis</i> , 2022, 78, 102427.	7.0	19
12	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021, 127, 96-107.	1.3	15
13	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-negative Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. <i>European Urology</i> , 2021, 79, 20-29.	0.9	13
14	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.2	13
15	When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers. <i>Cancer Treatment Reviews</i> , 2017, 58, 14-21.	3.4	12
16	Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE. <i>British Journal of Radiology</i> , 2020, 93, 20200819.	1.0	11
17	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. <i>Cancers</i> , 2021, 13, 1985.	1.7	10
18	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1028-1031.	2.0	10

#	ARTICLE	IF	CITATIONS
19	Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRIâ€characterized prostates. <i>Prostate</i> , 2018, 78, 1229-1237.	1.2	9
20	Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out. <i>BJU International</i> , 2021, 127, 169-170.	1.3	5
21	Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?. <i>British Journal of Radiology</i> , 2022, 95, 20210321.	1.0	5
22	Magnetic Resonance Imagingâ€guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies. <i>European Urology Open Science</i> , 2022, 38, 40-43.	0.2	5
23	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. <i>Scientific Reports</i> , 2020, 10, 17177.	1.6	4
24	Adaptable Image Quality Assessment Using Meta-Reinforcement Learning of Task Amenability. <i>Lecture Notes in Computer Science</i> , 2021, , 191-201.	1.0	4
25	A Case of Persistent Foot Pain in a Neurofibromatosis Type I Patient. <i>Case Reports in Medicine</i> , 2012, 2012, 1-3.	0.3	2
26	Isolated bilateral simplex ureteric ectopia: Bladder capacity as an indicator of continence outcome. <i>Journal of Pediatric Urology</i> , 2017, 13, 493.e1-493.e9.	0.6	2
27	Mycobacterial immunotherapy for prostate cancer: where can we go from here?. <i>Nature Reviews Urology</i> , 2020, 17, 189-190.	1.9	2
28	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. <i>Prostate</i> , 2022, 82, 876-879.	1.2	2
29	Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and Quality. <i>Urology</i> , 2021, 148, 316-317.	0.5	1
30	Morphological Change Forecasting For Prostate Glands Using Feature-Based Registration And Kernel Density Extrapolation. , 2021, , .		1
31	MP51-12 A TRAINING COURSE FOR THE UROLOGIST IMPROVES THEIR ABILITY TO INTERPRET CLINICALLY SIGNIFICANT PROSTATE CANCER ON MULTIPARAMETRIC MRI. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
32	Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carrollâ€™s Letter to the Editor re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443â€51. <i>European Urology</i> , 2020, 78, e112-e113.	0.9	0
33	Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Brigantiâ€™s Letter to the Editor re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imagingâ€based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443â€51. <i>European Urology</i> , 2020, 78, e166.	0.9	0
34	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Letter.. <i>Journal of Urology</i> , 2021, 205, 1233-1234.	0.2	0
35	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.. <i>Journal of Urology</i> , 2021, 205, 1526-1528.	0.2	0
36	Can MRI Replace Biopsy in Men on Surveillance?. <i>Current Clinical Urology</i> , 2018, , 111-119.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. Journal of Urology, 2020, 204, 1065-1066.	0.2	0